| 1 |
34050611 | Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. | 2022 Feb |
2 |
| 2 |
34151456 | Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship. | 2022 Feb |
1 |
| 3 |
34473525 | Recent Advances in the Management of Metastatic Prostate Cancer. | 2022 Jan |
1 |
| 4 |
34629045 | Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair. | 2022 |
1 |
| 5 |
34670865 | GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. | 2022 Feb |
1 |
| 6 |
34732853 | Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. | 2022 Jan |
1 |
| 7 |
34812476 | Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review). | 2022 Jan |
2 |
| 8 |
34854226 | Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. | 2022 Apr |
1 |
| 9 |
34880123 | cAMP-Mediated Autophagy Promotes Cell Survival via ROS-Induced Activation of PARP1: Implications for Treatment of Acute Lymphoblastic Leukemia. | 2022 Mar 1 |
1 |
| 10 |
34954029 | FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. | 2022 Jan |
1 |
| 11 |
34969765 | Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells. | 2022 Jan |
4 |
| 12 |
35000525 | Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. | 2022 Dec 31 |
2 |
| 13 |
35091172 | Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. | 2022 Feb 15 |
1 |
| 14 |
35097256 | Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide. | 2022 Jan 25 |
1 |
| 15 |
35130631 | PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-кB pathway activity and DNA damage response induced by Idarubicin | 2022 Jan 25 |
3 |
| 16 |
35156571 | Durable Disease-Free Survival in a Patient with Metastatic Triple-Negative Breast Cancer Treated With Olaparib Monotherapy. | 2022 Feb 14 |
2 |
| 17 |
35159068 | Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? | 2022 Feb 4 |
1 |
| 18 |
35163037 | Sesquiterpene Lactones Potentiate Olaparib-Induced DNA Damage in p53 Wildtype Cancer Cells. | 2022 Jan 20 |
2 |
| 19 |
35163134 | THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. | 2022 Jan 21 |
1 |
| 20 |
35165509 | Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis. | 2022 |
2 |
| 21 |
35188042 | Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. | 2022 Feb 20 |
2 |
| 22 |
35191009 | Genetic medicine is accelerating in Japan. | 2022 Feb 21 |
1 |
| 23 |
35194903 | XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. | 2022 May |
4 |
| 24 |
35205643 | Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. | 2022 Feb 11 |
2 |
| 25 |
35267438 | DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy. | 2022 Feb 23 |
1 |
| 26 |
35269669 | Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo. | 2022 Feb 25 |
2 |
| 27 |
35324529 | Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. | 2022 Mar 23 |
2 |
| 28 |
35343196 | A review on mechanisms of resistance to PARP inhibitors. | 2022 Mar |
1 |
| 29 |
35400012 | Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib. | 2022 Jan-Feb |
3 |
| 30 |
35408930 | Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells. | 2022 Mar 25 |
1 |
| 31 |
35419627 | An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. | 2022 May |
2 |
| 32 |
35444023 | Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer. | 2022 Apr 20 |
1 |
| 33 |
35466317 | Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. | 2022 |
2 |
| 34 |
35480123 | Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation. | 2022 |
1 |
| 35 |
35486574 | Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. | 2022 |
3 |
| 36 |
35494030 | Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review. | 2022 |
2 |
| 37 |
35517402 | Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. | 2022 |
2 |
| 38 |
35545049 | The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. | 2022 May 10 |
2 |
| 39 |
35593736 | First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. | 2022 May 20 |
1 |
| 40 |
35611209 | Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. | 2022 Apr 16 |
3 |
| 41 |
35619904 | OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells. | 2022 |
1 |
| 42 |
35624090 | FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2'-deoxycytidine and 5-hydroxymethyl-2'-deoxyuridine. | 2022 May 27 |
2 |
| 43 |
35628590 | Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. | 2022 May 21 |
1 |
| 44 |
35636395 | Parp Inhibition and Beyond in Brca- Associated Breast Cancer in Women: A State- Of- The- Art Summary of (Pre) - Clinical Research into Risk Reduction and Clinical Benefits. | 2022 May 30 |
1 |
| 45 |
32079692 | Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. | 2021 Jan 1 |
1 |
| 46 |
32164505 | A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. | 2021 |
1 |
| 47 |
32409690 | TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. | 2021 Feb |
1 |
| 48 |
32790034 | PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. | 2021 Jan |
2 |
| 49 |
32814472 | Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer. | 2021 Jun |
1 |
| 50 |
33069804 | Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib. | 2021 Feb 15 |
4 |